MammaPrint in Chinese Women

Protocol: 
P-0125

The Study of Molecular Risk Panels in Chinese Breast Cancer Patient using Mammaprint, TargetPrint, BluePrint and Research Gene Panel assays.

The Mammaprint study is a genetic study among Chinese women with breast cancer. The purpose of this study is to identify molecular factors or biomarkers that may be used to assess risk for breast cancer in this population. Identification of such markers could facilitate better risk assessment, detection methods, as well as development of better-targeted therapies. 

In this study, patients first undergo surgery to remove their breast cancer. Samples of their tissue are then sent for genetic analysis, and DNA testing is performed on blood samples. 

Results will be used to identify molecular characteristics and biomarkers in premenopausal Chinese women with breast cancer; to compare the MammaPrint Risk assessment outcomes with conventionally used risk assessments determined by clinical parameters, standard staging and IHC analysis; to identify correlations between molecular classifications and clinical characteristics such as hormonal receptor status, grade, prognosis; and to identify correlations between treatment outcomes and MammaPrint profile results. 

Are you Eligible? (Inclusion Criteria)

Eligible participants include women aged 18- 70, of Chinese origin, diagnosed with Stage 1 or 2 breast cancer

Specialty Area(s)

Trial Location

NYP/Columbia Division of Breast Surgery
HIP
New York City, NY 10032
United States